Head spinning from all of the data released at last week’s ASH conference in New Orleans? The Multiple Myeloma Research Foundation (MMRF) just released a summary of the important drug related myeloma news from ASH:
Data showed Revlimid and dexamethasone to treat patients with high-risk smoldering multiple myeloma prolonged time to progression, including complete responses, with manageable toxicity.
Preliminary clinical data was presented on elderly patients newly diagnosed with multiple myeloma who received Revimid in combination with melphalan and prednisone, followed by Revlimid alone compared with those who received MPR followed by placebo.
Clinical data was presented on myeloma patients younger than 65 who received either Revlimid, melphalan and prednisone or melphalan plus autologous stem cell transplant following an induction treatment of Revlimid plus low-dose dexamethason.
Follow-up clinical trial data showed previously untreated myeloma patients treated with Velcade, melphalan and prednisone had significantly longer overall survival at three years than patients treated with melphalan and prednisone. Read the release.
Phase III clinical trial data showed Velcade-based combinations for patients with previously untreated multiple myeloma had two-year survival rates of up to 88%. Data on the use of Velcade, intravenous cyclophosphamide and dexamethasone induction for previously untreated myeloma patients also was presented at the ASH annual meeting.
I will get you a copy of the experimental novel therapy agent summary tomorrow.
Feel good and keep smiling! Pat